1. Scrip

Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat

 
• By Dexter Jie Yan

Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.

save on R&D spending
More Chinese biotechs seek to conserve cash by reshuffling pipelines • Source: Shutterstock

Six Chinese biotechs are reshuffling their research and development programs to conserve funds amid the persistent downturn in the sector, the companies disclosed in their annual results for 2022.

While more resource-rich domestic drug makers are still bent on cramming into the already overcrowded immuno-oncology market in China, their cash-strapped peers have opted to withdraw from the cutthroat competition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia